Poland· PL-100528690
Zvogra
A denosumab product containing denosumabum, registered in Poland by STADA Arzneimittel AG. The same ATC class is registered in 16 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Denosumab is registered in 16 of 19 countries.
Countries holding a registration under ATC M05BX04 (denosumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Denosumab · ATC M05BX04
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of denosumab costs, country by country.
Normalised to the WHO defined daily dose (0.33 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Denosumab · price per daily dose (0.33 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.37
The record
At a glance
URPL (Poland)- Active substance
- Denosumabum
- Manufacturer
- STADA Arzneimittel AG
- Country
- Poland (PL)
- ATC code
- M05BX04
- ATC class
- Denosumab
- Defined daily dose
- 0.33 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin04150197250941
- gtin04150197251023
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
262 interactions on record for denosumab.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Denosumab · interactions on record
262 records
- 3 severe
- 259 moderate
Most severe, free to view
- EtelcalcetideH05BX04severe
- CladribineL01BB04severe
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Denosumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBILPREVDASciencepharma Sp. z o.o., Varšava
- BelgiumBilprevda 120 mgSciencePharma
- SwedenBilprevda 120 mg Injektionsvätska, lösningSciencepharma Sp. z o.o.
- IcelandBILPREVDASciencepharma Sp. z o.o.
- SpainBILPREVDA 120 MG SOLUCION INYECTABLESciencepharma Sp. Z O.O.
- NorwayOsenveltCelltrion Healthcare Hungary Kft.
- United KingdomXgeva 120mg/1ml solution for injection pre-filled syringesAmgen Ltd
- SwitzerlandXGEVA 120 mg, InjektionslösungAmgen Switzerland AG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Enwylma, Ponlimsi
- Iceland · Bildyos, Bilprevda
- Liechtenstein · Bildyos, Bilprevda
- Norway · Bildyos, Bilprevda
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ca4d7efc-4e32-4041-a08f-71e28cc111cc GET /v1/drugs/ca4d7efc-4e32-4041-a08f-71e28cc111cc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "120 mg",
"packaging": "04150197250941 ¦ Rpz ¦ EU/1/25/1981/001 ¦ 164801\n1 fiol. 1,7 ml\n04150197251023 ¦ Rpz ¦ EU/1/25/1981/002 ¦ 164802\n3 fiol. 1,7 ml\nRpz ¦ EU/1/25/1981/003 ¦ 164803\n4 fiol. 1,7 ml",
"substance": "Denosumabum 120 mg",
"common_name": "Denosumabum",
"pl_product_id": "100528690",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about denosumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.